https://phrma.org/blogs/rss PhRMA Blog RSS Feed for Sitecore Send Repeatable Campaigns en-us 13594 https://phrma.org/blog/mfn-won-t-lower-costs-when-insurers-call-the-shots Brianna Allen, May 8, 2026 MFN ties U.S. drug prices to other countries, but it won’t guarantee lower costs for patients. That’s because insurers still control the decisions that matter to Americans — which medicines are covered, what hurdles patients can face like prior authorization, and how much they pay out of pocket at the pharmacy. Fri, 08 May 2026 15:27:00 GMT 13589 https://phrma.org/blog/hospitals-in-the-hot-seat-congress-sharpens-focus-on-340b-consolidation-and-rising-costs Eliza Maciag, May 7, 2026 The recent House Ways & Means hearing on rising health care costs marked a notable escalation in congressional scrutiny of hospital pricing, consolidation and 340B-related abuses, particularly from Chairman Jason Smith. Thu, 07 May 2026 18:12:35 GMT 13587 https://phrma.org/blog/advancing-mental-health-in-may-and-beyond Kristen Booze, May 7, 2026 The reality: Nearly one in four adults in the U.S. experienced a mental health condition in the past year, and many did not get the care they needed. That gap between need and treatment is what makes Mental Health Awareness Month so important each May. It’s a reminder of something both simple and urgent: Mental health is health. And when patients are sick, they may need a medicine as part of their treatment plan. Thu, 07 May 2026 17:09:21 GMT 13579 https://phrma.org/blog/new-goldmine-ad-reveals-hospitals-hide-how-they-profit-from-340b-markups Elise Shutzer, May 6, 2026 PhRMA launched a new ad campaign today to highlight how large, non-profit hospitals are exploiting the 340B program for profits that can be used in egregious ways with no patient benefit.   Wed, 06 May 2026 04:00:00 GMT 13578 https://phrma.org/blog/ustr-s-2026-special-301-report-stands-up-for-american-innovation Ernest Kawka, May 4, 2026 Last week, the Office of the United States Trade Representative (USTR) released its 2026 Special 301 Report. The annual report highlights foreign government policies that unfairly limit American innovation.  Mon, 04 May 2026 17:03:39 GMT 13575 https://phrma.org/blog/guest-blog-how-mfn-price-controls-could-decide-my-health-care Guest Contributor, April 30, 2026 Voters for Cures works to drive patient-centered progress in innovation, affordability and access and pushes for necessary, positive and long-term change to better address the needs of diverse patient communities. Sue M. is a Voters for Cures patient advocate who is sharing her story about living with diabetes. Thu, 30 Apr 2026 04:00:00 GMT 13570 https://phrma.org/blog/a-program-off-track-how-340b-drives-both-hospital-consolidation-and-system-gaming Eliza Maciag, April 27, 2026 What's happening: Due to little oversight and no transparency of the federal 340B program, tax-exempt hospitals and clinics are able to exploit the program to boost profits at the expense of patients, taxpayers and employers. These behaviors are drawing growing scrutiny from Congress, the administration and outside voices, including the Washington Post Editorial Board.  Mon, 27 Apr 2026 21:06:31 GMT 13555 https://phrma.org/blog/washington-post-editorial-board-says-340b-has-become-corporate-welfare Molly Jenkins, April 27, 2026 The Washington Post Editorial Board is the latest to join the chorus of voices calling for federal reform of the 340B Program. The Board warns that unchecked growth has turned 340B into a profit center for large hospital systems, driving up costs for everyone else. Mon, 27 Apr 2026 04:00:00 GMT 13554 https://phrma.org/blog/briefing-capitol-hill-panel-on-healthcare-denial-crisis-in-america Mike Ybarra, April 24, 2026 This week, I had the privilege of moderating a Capitol Hill briefing that brought together physicians, researchers and patient advocates to confront a growing crisis: insurance denials and their impact on care. The briefing focused on the findings of a landmark analysis, "70% DENIED: How insurance denials are delaying and preventing care for millions of Americans." Fri, 24 Apr 2026 14:30:01 GMT 13553 https://phrma.org/blog/world-immunization-week-putting-preventable-diseases-in-the-past Mike Ybarra, April 24, 2026 There are diseases I was trained to recognize as a physician that I’ve rarely—or never—had to treat. Diseases like Respiratory syncytial virus and Haemophilus influenzae type b—once common causes of crowded emergency rooms and pediatric wards—have declined significantly, not by chance, but because of vaccines. World Immunization Week presents a moment to reflect on what made this progress possible.  Fri, 24 Apr 2026 04:00:00 GMT 13549 https://phrma.org/blog/mfn-price-controls-would-drain-pensions-and-put-retirements-at-risk Brianna Allen, April 23, 2026 A new analysis by NDP Analytics shows that harmful policies like Most Favored Nation price controls threaten far more than patient access and biopharmaceutical innovation. They would directly weaken the retirement security of millions of Americans.  Thu, 23 Apr 2026 13:06:56 GMT 13545 https://phrma.org/blog/survey-confirms-too-many-insured-americans-face-barriers-to-reliable-health-care Elise Shutzer, April 22, 2026 Health insurance coverage should ensure reliable access to care. For too many Americans, that simply isn’t the case.  Wed, 22 Apr 2026 15:14:55 GMT 13538 https://phrma.org/blog/pdufa-creates-an-efficient-drug-review-process-that-benefits-american-patients Lucy Vereshchagina, PhD, April 22, 2026 The Prescription Drug User Fee Act (PDUFA) is essential to maintaining America’s leadership in drug development and ensuring patients have timely access to new treatments.  Wed, 22 Apr 2026 04:00:00 GMT 13537 https://phrma.org/blog/cnbc-maintaining-america-s-lead-in-medical-innovation Stephen J. Ubl, April 21, 2026 The U.S. biopharmaceutical industry is a crown jewel of the American economy and a cornerstone of U.S. competitiveness and national security. Tue, 21 Apr 2026 18:10:59 GMT